BioAtla, Inc. (NASDAQ:BCAB) Receives Consensus Recommendation of “Hold” from Analysts

BioAtla, Inc. (NASDAQ:BCAB) has been given a consensus recommendation of “Hold” by the five brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $4.00.

BCAB has been the topic of several analyst reports. Rodman & Renshaw started coverage on shares of BioAtla in a report on Tuesday. They issued a “buy” rating and a $4.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioAtla in a research report on Friday.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BCAB. Acorn Capital Advisors LLC raised its position in shares of BioAtla by 19.9% during the second quarter. Acorn Capital Advisors LLC now owns 4,835,111 shares of the company’s stock worth $1,915,000 after purchasing an additional 803,065 shares during the period. Vanguard Group Inc. increased its stake in BioAtla by 9.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock worth $1,339,000 after purchasing an additional 162,647 shares in the last quarter. Acadian Asset Management LLC raised its holdings in BioAtla by 968.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after buying an additional 1,531,994 shares during the period. Millennium Management LLC acquired a new stake in BioAtla during the 3rd quarter worth approximately $235,000. Finally, Susquehanna International Group LLP lifted its stake in BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after buying an additional 177,760 shares in the last quarter. 77.23% of the stock is currently owned by institutional investors.

BioAtla Trading Down 2.1%

NASDAQ BCAB traded down $0.01 during trading on Tuesday, reaching $0.31. 4,455,774 shares of the company’s stock were exchanged, compared to its average volume of 2,532,207. BioAtla has a fifty-two week low of $0.24 and a fifty-two week high of $1.43. The firm has a market capitalization of $18.12 million, a PE ratio of -0.27 and a beta of 1.04. The company’s fifty day simple moving average is $0.74 and its 200-day simple moving average is $0.61.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. Equities analysts forecast that BioAtla will post -1.46 EPS for the current fiscal year.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.